<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1.0"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/2e6751bfd7d36be9-s.p.otf" as="font" crossorigin="" type="font/otf"/><link rel="preload" href="/_next/static/media/90b139f15f0b76e6-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/d567f6e95faecdec-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo-white.svg"/><link rel="preload" as="image" href="/images/clinical-trials-hero-banner.jpg"/><link rel="preload" as="image" href="./keyboard_arrow_down_24dp_FFFFFF_FILL0_wght400_GRAD0_opsz24.svg"/><link rel="preload" as="image" href="./close_24dp_FFFFFF_FILL0_wght400_GRAD0_opsz24.svg"/><link rel="stylesheet" href="/_next/static/css/ec2da9187a4470db.css" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/fd5e99a03139be66.css" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/cc7f9291227535e2.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-aa9bcb5c9631707d.js"/><script src="/_next/static/chunks/4bd1b696-50475f753be88232.js" async=""></script><script src="/_next/static/chunks/684-0a0fc973a5af6627.js" async=""></script><script src="/_next/static/chunks/main-app-8ad8e4587862f10f.js" async=""></script><script src="/_next/static/chunks/37-a26b13f87ab29070.js" async=""></script><script src="/_next/static/chunks/125-7df5ca76a782050a.js" async=""></script><script src="/_next/static/chunks/701-074e06a1b07af3d9.js" async=""></script><script src="/_next/static/chunks/420-1993ecc7d3547568.js" async=""></script><script src="/_next/static/chunks/816-8e3116e3fd24d1f0.js" async=""></script><script src="/_next/static/chunks/app/layout-bab7f84191e188c2.js" async=""></script><script src="/_next/static/chunks/278-a20f3f37cd2168a3.js" async=""></script><script src="/_next/static/chunks/910-d8833b5eb1740328.js" async=""></script><script src="/_next/static/chunks/722-65461a18c3229669.js" async=""></script><script src="/_next/static/chunks/945-635cfbeb3bb5f567.js" async=""></script><script src="/_next/static/chunks/458-baba401b42b3259e.js" async=""></script><script src="/_next/static/chunks/220-f3cafd169a707a9a.js" async=""></script><script src="/_next/static/chunks/app/(pages)/layout-66e0a35eb32f6f03.js" async=""></script><script src="/_next/static/chunks/473-dd0af661bef7f314.js" async=""></script><script src="/_next/static/chunks/582-7d7f0c699365d581.js" async=""></script><script src="/_next/static/chunks/977-6a880f93ab31fcff.js" async=""></script><script src="/_next/static/chunks/app/(pages)/clinical-trials/page-80c37838abeaa982.js" async=""></script><link rel="preload" href="https://www.googletagmanager.com/gtag/js?id=G-LV8VQ0CQB3" as="script"/><link rel="preload" href="https://cookie-cdn.cookiepro.com/scripttemplates/otSDKStub.js" as="script"/><meta name="next-size-adjust" content=""/><title>Revolution Medicines - Clinical Trials</title><link rel="icon" type="image/png" href="favicon.webp"/><meta name="description" content="Revolution Medicines is evaluating potential treatments for RAS mutant cancers through our clinical trials. Explore how you can participate or get involved."/><meta name="keywords" content="clinical trials, medical research, health studies, RevMed"/><meta name="author" content="Revolution Medicine"/><meta property="og:title" content="Revolution Medicines - Clinical Trials"/><meta property="og:description" content="Revolution Medicines is evaluating potential treatments for RAS mutant cancers through our clinical trials. Explore how you can participate or get involved."/><meta property="og:image" content="/images/dvm2tsz9xinsvc7axcj7-1.jpg"/><meta property="og:url" content="https://www.revmedclinicaltrials.com"/><meta property="og:type" content="website"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="Revolution Medicines - Clinical Trials"/><meta name="twitter:description" content="Revolution Medicines is evaluating potential treatments for RAS mutant cancers through our clinical trials. Explore how you can participate or get involved."/><meta name="twitter:image" content="/images/dvm2tsz9xinsvc7axcj7-2.jpg"/><meta name="twitter:url" content="https://www.revmedclinicaltrials.com"/><meta property="og:site_name" content="Revolution Medicines - Clinical Trials"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="150x176"/><script>(self.__next_s=self.__next_s||[]).push(["https://cookie-cdn.cookiepro.com/scripttemplates/otSDKStub.js",{"type":"text/javascript","charset":"UTF-8","data-domain-script":"0196907c-3985-7f5e-92c8-3d7a331bc411"}])</script><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule=""></script></head><body class="__variable_ee2c22 __variable_fa6f5f __variable_acae22 antialiased"><div class="LandingModal_container__SOYWJ"><div class="LandingModal_header__Nh40I"><img alt="logo" width="150" height="80" src="/logo-white.svg"/></div><div class="LandingModal_inner__Pk0Ay"><h1 class="text-center text-3xl md:text-5xl">Welcome to Revolution Medicines</h1><p class="md:text-1xl max-w-[40rem] text-center text-[1rem] text-white">Our RAS(ON) inhibitor clinical trials are intended to evaluate safety and efficacy in patients with RAS mutant cancers with unmet medical need</p><p class="py-4 text-center text-[1rem] text-white md:py-10 md:text-[1.5rem]">To get started, please let us know if you are an interested healthcare professional</p><a href="/"><div class="Button2_button__yK7tg Button2_white__aNyys "><p class="md:text-1xl text-center text-[1rem] text-white">Yes, I am a Healthcare Professional</p></div></a><a href="/"><div class="Button2_button__yK7tg Button2_white__aNyys "><p class="md:text-1xl text-center text-[1rem] text-white">No, I am not a Healthcare Professional</p></div></a></div><div class="LandingModal_background-image__9FiUi" style="background-image:url(&#x27;logo-outline.svg&#x27;)"></div></div><div class="shell"><div class="shell-primary-header"><div class="relative isolate mt-[1.75rem] h-full w-full" style="filter:drop-shadow(2px 2px 4px rgba(0, 0, 0, 0.1))"><ul class="absolute top-0 z-10 flex h-12 w-full flex-row items-center justify-between gap-4 overflow-hidden rounded-2xl bg-white px-6 py-3 sm:h-16 xl:-translate-x-[0.5rem]"><li class="shrink-0"><a href="/"><button data-slot="button" class="cursor-pointer inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive h-9 px-4 py-2 has-[&gt;svg]:px-3 scale-140 hover:cursor-pointer"><img alt="Revolution Medicines" loading="lazy" width="100" height="100" decoding="async" data-nimg="1" style="color:transparent" src="/images/lottie-logo.svg"/></button></a></li><li class="grow"></li><li class="relative hidden shrink-0 cursor-pointer lg:flex"><a target="_self" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-«Ron6bedb»" data-state="closed" data-slot="popover-trigger" href="/clinical-trials"><button data-slot="button" class="cursor-pointer justify-center whitespace-nowrap disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive h-9 px-4 py-2 has-[&gt;svg]:px-3 text-primary hover:text-accent flex w-full flex-row items-center gap-2 rounded-md text-[1rem] leading-7 font-normal transition-all duration-300 hover:cursor-pointer"><span class="text-primary hidden transition-all duration-300 md:block" style="color:white">Clinical Trials</span></button></a><div class="bg-accent absolute -bottom-0 left-1/2 z-[-1] h-full w-full -translate-x-1/2 rounded-sm"></div></li><li class="relative hidden shrink-0 cursor-pointer lg:flex"><a target="_self" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-«Rp76bedb»" data-state="closed" data-slot="popover-trigger" href="/hcps"><button data-slot="button" class="cursor-pointer justify-center whitespace-nowrap disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive h-9 px-4 py-2 has-[&gt;svg]:px-3 text-primary hover:text-accent flex w-full flex-row items-center gap-2 rounded-md text-[1rem] leading-7 font-normal transition-all duration-300 hover:cursor-pointer"><span class="text-primary hidden transition-all duration-300 md:block" style="color:unset">Healthcare Professionals</span></button></a></li><li class="relative hidden shrink-0 cursor-pointer lg:flex"><a target="_self" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-«Rpn6bedb»" data-state="closed" data-slot="popover-trigger" href="/patients"><button data-slot="button" class="cursor-pointer justify-center whitespace-nowrap disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive h-9 px-4 py-2 has-[&gt;svg]:px-3 text-primary hover:text-accent flex w-full flex-row items-center gap-2 rounded-md text-[1rem] leading-7 font-normal transition-all duration-300 hover:cursor-pointer"><span class="text-primary hidden transition-all duration-300 md:block" style="color:unset">Patients</span></button></a></li><li class="relative hidden shrink-0 cursor-pointer lg:flex"><a target="_blank" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-«Rq76bedb»" data-state="closed" data-slot="popover-trigger" href="https://www.revmed.com/"><button data-slot="button" class="cursor-pointer justify-center whitespace-nowrap disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive h-9 px-4 py-2 has-[&gt;svg]:px-3 text-primary hover:text-accent flex w-full flex-row items-center gap-2 rounded-md text-[1rem] leading-7 font-normal transition-all duration-300 hover:cursor-pointer"><span class="text-primary hidden transition-all duration-300 md:block" style="color:unset">About RevMed</span></button></a></li><button data-slot="dialog-trigger" class="cursor-pointer items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive shadow-xs size-9 text-primary-foreground flex bg-transparent hover:bg-transparent lg:hidden" aria-label="Toggle menu" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-«R96bedb»" data-state="closed"><svg viewBox="0 0 4 4" overflow="visible" preserveAspectRatio="none" width="24" height="24"><line x1="0" x2="4" y1="0" y2="0" stroke="var(--menu-button-color, currentColor)" stroke-width="2" vector-effect="non-scaling-stroke"></line><line x1="0" x2="4" y1="2" y2="2" stroke="var(--menu-button-color, currentColor)" stroke-width="2" vector-effect="non-scaling-stroke" opacity="1"></line><line x1="0" x2="4" y1="4" y2="4" stroke="var(--menu-button-color, currentColor)" stroke-width="2" vector-effect="non-scaling-stroke"></line></svg></button></ul></div><div class="relative top-[4.75rem] -z-10 ml-auto flex -translate-x-[0.5rem] flex-col items-end gap-[0.25rem] lg:flex-row lg:gap-[1rem]"><button type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-«Rjedb»" data-state="closed" data-slot="dialog-trigger"><div data-slot="button" class="cursor-pointer inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive bg-background text-foreground hover:bg-background/90 h-10 rounded-lg px-6 has-[&gt;svg]:px-4 mix-blend-plus-darker shadow-2xl"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 30 28" fill="none"><g fill="#1E6B5C" stroke="#1E6B5C" stroke-miterlimit="10" stroke-width="0.5" clip-path="url(#a)"><path d="M24.272 16.952c-1.835-1.83-4.606-1.431-6.184.518a.468.468 0 0 1-.658 0l-6.95-6.981c-.43-.455.25-.875.516-1.18a4.03 4.03 0 0 0 1.174-2.846 4.03 4.03 0 0 0-1.174-2.847L8.599 1.21a3.513 3.513 0 0 0-4.957.004L2.072 2.79A6.487 6.487 0 0 0 .186 7.364c0 1.716.677 3.358 1.88 4.57l13.928 13.99a6.427 6.427 0 0 0 9.104 0l1.57-1.578a3.556 3.556 0 0 0 0-4.987l-2.397-2.407Zm1.65 6.643-1.571 1.577a5.365 5.365 0 0 1-7.605-.004L2.82 11.185a5.413 5.413 0 0 1-1.574-3.82c0-1.43.565-2.805 1.574-3.819l1.57-1.577a2.45 2.45 0 0 1 3.466 0l2.397 2.407a2.983 2.983 0 0 1 0 4.187l-.516.518a1.535 1.535 0 0 0 0 2.164l6.95 6.98a1.518 1.518 0 0 0 2.154 0l.516-.517a2.956 2.956 0 0 1 4.172 0l2.397 2.407c.953.961.953 2.52 0 3.481h-.004Z"></path><path d="M29.312 4.078a1.574 1.574 0 0 0-1.088-.435H13.273a.532.532 0 0 0-.531.533.53.53 0 0 0 .53.533h14.6l-8.296 7.27a.521.521 0 0 1-.688 0l-4.991-4.367a.53.53 0 1 0-.695.8l2.217 1.941-1.361 1.518a.53.53 0 1 0 .785.713l1.376-1.532 1.97 1.728a1.572 1.572 0 0 0 2.083 0l1.974-1.728 5.85 6.493h-.459a.532.532 0 0 0-.53.533.53.53 0 0 0 .53.534h.59c.876 0 1.586-.714 1.59-1.596V5.235c0-.44-.18-.86-.497-1.157h-.008Zm-.557 1.262v11.345l-5.713-6.343 5.713-5.006v.004Z"></path></g><defs><clipPath id="a"><path fill="#fff" d="M0 0h30v28H0z"></path></clipPath></defs></svg>Contact Us</div></button></div></div><main class="shell-main"><div id="stack-root" class="stack-layout justify-center"><div class="relative col-span-full row-span-3 grid grid-cols-subgrid grid-rows-subgrid"><div class="stack-full-bleed"></div><div id="stack-main-column" class="relative grid max-w-full gap-24 sm:gap-40 stack-full-bleed"><div id="grid-24-container" class="@container/grid-cols-24 grid w-full grid-flow-dense grid-cols-24"><div id="stack-subgrid-item" class="@container isolate grid gap-2 col-span-full pb-0 pt-0"><div class="bg-primary relative h-96 w-full overflow-hidden 2xl:h-[40rem]"><img src="/images/clinical-trials-hero-banner.jpg" class="absolute inset-0 mx-auto h-full w-full object-cover object-[50%_40%]"/></div></div></div></div></div><div class="relative col-span-full row-span-3 grid grid-cols-subgrid grid-rows-subgrid bg-primary"><div class="stack-full-bleed"></div><div id="stack-main-column" class="relative grid max-w-full gap-24 sm:gap-40 stack-main"><div id="grid-24-container" class="@container/grid-cols-24 grid w-full grid-flow-dense grid-cols-24"><div id="stack-subgrid-item" class="@container isolate grid gap-2 col-span-full pb-0 pt-0"><h1 class="mt-[3rem] mb-0!">Clinical Trials</h1></div></div></div><div class="relative isolate h-12 w-full stack-full-bleed bump-botom"><div class="absolute inset-0 -z-0 bg-muted"></div><div class="absolute inset-0 z-0 bg-primary rounded-bl-full"></div></div></div><div id="select-clinical-trials" class="relative col-span-full row-span-3 grid grid-cols-subgrid grid-rows-subgrid bg-muted pt-12"><div class="stack-item-background -z-0 bg-cover bg-no-repeat!"><div class="bg-muted h-full w-full"></div></div><div class="stack-full-bleed"></div><div id="stack-main-column" class="relative grid max-w-full gap-24 sm:gap-40 stack-main"><div id="grid-24-container" class="@container/grid-cols-24 grid w-full grid-flow-dense grid-cols-24"><div id="stack-subgrid-item" class="@container isolate grid gap-2 col-span-full pb-0 pt-0 bg-muted text-muted-foreground" style="opacity:0;transform:translateY(20px)"><div class="flex w-full flex-col gap-4"><h2>Select Clinical Trials<!-- --> <span class="text-[]">of RAS(ON) Inhibitors</span></h2><p>At Revolution Medicines we are committed to the discovery, development, and delivery of targeted therapies for patients with RAS mutant cancer. Our RAS(ON) Inhibitor Clinical Trial Program is evaluating molecules aimed at targeting a broad range of RAS mutant cancers. Rat sarcoma (RAS) is a protein that is important in regulating cell division in our bodies. In certain cancers known as RAS mutant cancers, changes (or mutations) in the RAS gene cause the RAS protein to become mostly switched ON (or active), allowing the cancer cells to grow, spread, and survive.</p><h3>Investigational RAS(ON) inhibitors currently under development include:</h3><ul class="max-w-[55rem]"><li><b>Daraxonrasib (RMC-6236)</b>, an oral, RAS(ON) multi-selective inhibitor that is selective for the active or &quot;(ON)&quot; state of multiple mutant forms of RAS (G12X, G13X, Q61X)</li><li><b>Zoldonrasib (RMC-9805)</b>, an oral, RAS(ON) mutant-selective inhibitor that is selective for the active or &quot;(ON)&quot; state of RAS G12D</li><li><b>Elironrasib (RMC-6291)</b>, an oral, RAS(ON) mutant-selective inhibitor that is selective for the active or &quot;(ON)&quot; state of RAS G12C</li><li><b>RMC-5127</b>, an oral, RAS(ON) mutant-selective inhibitor that is selective for the active or &quot;(ON)&quot; state of RAS G12V</li></ul></div></div></div></div><div class="relative isolate h-12 w-full stack-full-bleed bump-botom"><div class="absolute inset-0 -z-0 bg-[#f5f8f9]!"></div><div class="absolute inset-0 z-0 bg-muted rounded-bl-full"></div></div></div><div id="rason-inhibitor-clinical-trial-program" class="relative col-span-full row-span-3 grid grid-cols-subgrid grid-rows-subgrid bg-[#f5f8f9]! pt-24 pb-12"><div class="absolute right-0 -bottom-12 left-0 h-12 bg-background"></div><div class="stack-full-bleed"></div><div id="stack-main-column" class="relative grid max-w-full gap-24 sm:gap-40 stack-main"><div id="grid-24-container" class="@container/grid-cols-24 grid w-full grid-flow-dense grid-cols-24"><div id="stack-subgrid-item" class="@container isolate grid gap-2 col-span-full pb-0 pt-0"><h2 class="text-[#1e6b5c]">RAS(ON) Inhibitor Clinical Trial Locator</h2><div class="relative h-[0.35rem] bg-[#d1dbd1]  mb-[2rem] w-[8rem] undefined"><div class="absolute h-full w-[50%] bg-black"></div></div><div class="relative bg-white"><div data-testid="map" class="CustomMap_map__mS_Y9"></div></div><h2 class="mt-[5rem] text-[#1e6b5c]">RAS(ON) Inhibitor Clinical Trial Program</h2><div class="mb-8"><div class="MapFilters_container__hOck3"><div><button class="DowndownMenu_input-button__PLsqr " aria-label="select region" type="button" id="radix-«Rar993rdedb»" aria-haspopup="menu" aria-expanded="false" data-state="closed"><div>region<!-- --> </div><div><img src="./keyboard_arrow_down_24dp_FFFFFF_FILL0_wght400_GRAD0_opsz24.svg"/></div></button><button class="DowndownMenu_input-button__PLsqr " aria-label="select country" type="button" id="radix-«Rir993rdedb»" aria-haspopup="menu" aria-expanded="false" data-state="closed"><div>country<!-- --> </div><div><img src="./keyboard_arrow_down_24dp_FFFFFF_FILL0_wght400_GRAD0_opsz24.svg"/></div></button><button disabled="" class="DowndownMenu_input-button__PLsqr DowndownMenu_input-button-disabled__eKXUQ" aria-label="select state" type="button" id="radix-«Rqr993rdedb»" aria-haspopup="menu" aria-expanded="false" data-state="closed" data-disabled=""><div>state<!-- --> </div><div><img src="./keyboard_arrow_down_24dp_FFFFFF_FILL0_wght400_GRAD0_opsz24.svg"/></div></button><button class="DowndownMenu_input-button__PLsqr " aria-label="select tumor" type="button" id="radix-«R12r993rdedb»" aria-haspopup="menu" aria-expanded="false" data-state="closed"><div>tumor<!-- --> </div><div><img src="./keyboard_arrow_down_24dp_FFFFFF_FILL0_wght400_GRAD0_opsz24.svg"/></div></button><button class="DowndownMenu_input-button__PLsqr " aria-label="select intervention" type="button" id="radix-«R1ar993rdedb»" aria-haspopup="menu" aria-expanded="false" data-state="closed"><div>intervention<!-- --> </div><div><img src="./keyboard_arrow_down_24dp_FFFFFF_FILL0_wght400_GRAD0_opsz24.svg"/></div></button></div><button class="MapFilters_button__bwznm">clear all<img src="./close_24dp_FFFFFF_FILL0_wght400_GRAD0_opsz24.svg"/></button></div><div class="relative h-[0.35rem] bg-[#d1dbd1] mt-[3rem] mb-[2rem] w-[8rem] undefined"><div class="absolute h-full w-[50%] bg-black"></div></div><p class="mt-10 mb-0!">Showing all trials</p></div><!--$--><div class="@container w-full bg-white"><div class="@tablet:grid @tablet:grid-cols-[min-content_1fr_1fr_minmax(150px, auto)_minmax(150px, auto)]"><div class="bg-primary text-primary-foreground @tablet:text-xl @tablet:grid col-span-5 hidden grid-cols-subgrid gap-x-3 px-3 py-3 text-lg font-medium"><div style="text-align:left">Type of Cancer</div><div style="text-align:left">Trial Description</div><div style="text-align:left">Select Eligibility Criteria<sup>a</sup></div><div style="text-align:center">Status<p class="mt-2 mb-0! max-w-[10rem] text-center text-[0.8rem] leading-4 text-white">Recruitment status may vary by trial site<sup>b</sup></p></div><div style="text-align:left">For More Information</div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300 border-t"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"><p class="font-[900]!">Pancreatic ductal adenocarcinoma (PDAC)</p></div><div class="@tablet:hidden block"><p>Pancreatic ductal adenocarcinoma (PDAC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RASolute 304 is a Phase 3 study designed to evaluate whether daraxonrasib (RMC-6236) will improve disease-free survival (DFS) compared to standard of care (SOC) observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease</li>
<li>Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy</li>
<li>Must have completed most recent treatment within the past 12 weeks</li>
<li>Documented RAS mutation status</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">actively recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct07252232"><p class="text-haze-green font-bold underline underline-offset-3">NCT07252232</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300 border-t"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"><p class="font-[900]!">Non-small cell lung cancer (NSCLC)</p></div><div class="@tablet:hidden block"><p>Non-small cell lung cancer (NSCLC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RASolve 301 is a Phase 3 trial designed to evaluate daraxonrasib (RMC‑6236) compared to docetaxel chemotherapy in patients with previously treated, locally advanced or metastatic RAS‑mutated NSCLC</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Confirmed locally advanced or metastatic disease</li>
<li>Documented RAS mutation status</li>
<li>No prior therapy with direct RAS‑targeted therapy or docetaxel</li>
<li>No untreated central nervous system metastatic disease</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">Actively Recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct06881784"><p class="text-haze-green font-bold underline underline-offset-3">NCT06881784</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300 border-t"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"><p class="font-[900]!">Pancreatic ductal adenocarcinoma (PDAC)</p></div><div class="@tablet:hidden block"><p>Pancreatic ductal adenocarcinoma (PDAC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RASolute 302 is a Phase 3 study that compares the RAS(ON) inhibitor daraxonrasib (RMC‑6236) with standard of care chemotherapy in patients with PDAC that has spread to other parts of the body (metastatic) and has been previously treated</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Male or female 18 years or older</li>
<li>Documented RAS mutation status, either mutant or wild type
<ul>
<li>RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)</li>
</ul>
</li>
<li>Previously treated with 1 prior line of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen</li>
<li>No history of known central nervous system metastatic disease</li>
<li>No previous RAS‑directed therapies</li>
<li>No major surgery within 4 weeks of starting the trial</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">active, not recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct06625320"><p class="text-haze-green font-bold underline underline-offset-3">NCT06625320</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300 border-t"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"><p class="font-[900]!">Non-small cell lung cancer (NSCLC)</p></div><div class="@tablet:hidden block"><p>Non-small cell lung cancer (NSCLC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RMC-LUNG-101 is a Phase 1b/2 study investigating 3 RAS(ON) inhibitors, elironrasib (RMC-6291), zoldonrasib (RMC-9805) and/or daraxonrasib (RMC-6236), with SOC, or zoldonrasib as monotherapy, in patients with advanced or metastatic NSCLC or other advanced solid tumors</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Male or female 18 years or older</li>
<li>KRAS G12C, RAS G12D, or other RAS mutations</li>
<li>Received prior standard therapy appropriate for tumor type and stage</li>
<li>No major surgery <br/> &lt;28 days of first dose</li>
<li>No primary central nervous system tumors</li>
<li>No active or history of interstitial lung disease or pneumonitis requiring steroids</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">actively recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct06162221"><p class="text-haze-green font-bold underline underline-offset-3">NCT06162221</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300 border-t"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"><p class="font-[900]!">Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)</p></div><div class="@tablet:hidden block"><p>Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RMC-5127-001 is a Phase 1/1b study investigating PK and preliminary clinical activity of RMC-5127, either as monotherapy or in combination with daraxonrasib (RMC-6236) or cetuximab, in patients with advanced or metastatic KRAS G12V mutant solid tumors, such as NSCLC, PDAC, and CRC</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Male or female 18 years or older</li>
<li>Documented KRAS G12V mutation</li>
<li>Received and progressed or been intolerant to prior standard therapy appropriate for tumor type and stage</li>
<li>No previous direct RAS‑targeted therapies (including G12V inhibitors)</li>
<li>No primary central nervous system tumors</li>
<li>Any conditions that may affect the ability to take or absorb study drug</li>
<li>Major surgery within 28 days prior to receiving study drug(s)</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">actively recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct07349537"><p class="text-haze-green font-bold underline underline-offset-3">NCT07349537</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"></div><div class="@tablet:hidden block"><p>Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RMC-9805-001 is a Phase 1/1b study that investigates zoldonrasib (RMC-9805) alone or in combination with daraxonrasib (RMC‑6236) in patients with advanced or metastatic solid tumors, such as NSCLC, PDAC, and CRC</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Male or female 18 years or older</li>
<li>KRAS G12D mutation</li>
<li>Received prior therapy</li>
<li>No previous RAS‑directed therapies</li>
<li>No primary central nervous system tumors or active brain metastasis</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">actively recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct06040541"><p class="text-haze-green font-bold underline underline-offset-3">NCT06040541</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"></div><div class="@tablet:hidden block"><p>Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RMC-GI-102 is a Phase 1/2 study that investigates 2 RAS(ON) inhibitors (daraxonrasib [RMC-6236] and zoldonrasib [RMC-9805]) combined with the standard of care or other new therapeutics in patients with metastatic solid tumors, such as CRC and PDAC</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Male or female 18 years or older</li>
<li>RAS mutations, including G12D</li>
<li>No primary central nervous system tumors or impaired gastrointestinal function</li>
<li>No major surgery within 28 days of first dose</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">actively recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct06445062"><p class="text-haze-green font-bold underline underline-offset-3">NCT06445062</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"></div><div class="@tablet:hidden block"><p>Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RMC-6291-101 is a Phase 1b study investigating the combination of RAS(ON) inhibitors elironrasib (RMC-6291) and daraxonrasib (RMC‑6236) in patients with advanced or metastatic solid tumors, such as NSCLC, CRC, and PDAC</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Male or female 18 years or older</li>
<li>KRAS G12C mutation</li>
<li>Received previous treatment</li>
<li>No primary central nervous system tumors or active brain metastasis</li>
<li>No major surgery within 28 days of first dose</li>
<li>No minor procedures within 7 days of treatment</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">actively recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct06128551"><p class="text-haze-green font-bold underline underline-offset-3">NCT06128551</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"></div><div class="@tablet:hidden block"><p>Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RMC-6291-001 is a Phase 1/1b dose-escalation and dose-expansion study investigating the RAS(ON) inhibitor elironrasib (RMC-6291) in patients with advanced or metastatic solid tumors, including NSCLC, CRC, and PDAC</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Male or female 18 years or older</li>
<li>KRAS G12C mutation</li>
<li>No primary central nervous system tumors or active brain metastasis</li>
<li>No major surgery within 28 days of first dose</li>
<li>No minor procedures within 7 days of treatment</li>
<li>Previously treated with standard of care (SOC) therapies for their respective tumor types, is intolerant to, or is considered ineligible for, SOC anticancer treatments</li>
<li>No previous treatment with a KRAS G12C(ON) inhibitor</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">active, not recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct05462717"><p class="text-haze-green font-bold underline underline-offset-3">NCT05462717</p></a></div></div><div class="@tablet:col-span-5 @tablet:grid-cols-subgrid border-accent @tablet:border-b-0 hover:bg-muted hover:text-muted-foreground grid grid-cols-1 gap-x-3 border-b px-3 py-6 transition-colors duration-300"><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[2rem]! mb-[1rem]! block p-0 font-bold">Type of cancer</p><div class="@tablet:block hidden"></div><div class="@tablet:hidden block"><p>Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)</p></div></div><div class="@tablet:text-base space-y-2 text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Trial Description</p><p>RMC-6236-001 a Phase 1/2 study that investigates the RAS(ON) inhibitor daraxonrasib (RMC‑6236) in adult patients with advanced solid tumors, including NSCLC, CRC, and PDAC</p></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Select Eligibility Criteria:<!-- --> </p><div><ul>
<li>Male or female 18 years or older</li>
<li>KRAS G12 or RAS mutations</li>
<li>Treatment naïve or received prior standard therapy appropriate for tumor type and stage</li>
<li>No central nervous system tumors or active brain metastasis</li>
<li>No history of an unstable medical condition that could affect their ability to take part in the trial</li>
</ul></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mb-[1rem]! block p-0 font-bold">Status:<br/> <span class="text-sm font-normal">(Recruitment status may vary by trial site<sup>b</sup></span>)</p><div><div class="bg-secondary rounded-[1rem] px-[1rem] py-[0.25rem] text-center text-xs text-white capitalize"><p class="mb-0! text-sm text-white">actively recruiting</p></div></div></div><div class="@tablet:text-base text-sm break-words"><p class="@tablet:hidden text-foreground mt-[3rem] mb-[1rem]! block p-0 font-bold">For more information:<!-- --> </p><a href="/clinical-trials/nct05379985"><p class="text-haze-green font-bold underline underline-offset-3">NCT05379985</p></a></div></div></div></div><!--/$--><p class="text-xs"><sup>a</sup>This is not a complete list of eligibility criteria; for more information, please go to ClinicalTrials.gov. <sup>b</sup>To view site-level status information, please go to ClinicalTrials.gov.</p></div></div></div></div><div id="rason-inhibitor-clinical-trial-program" class="relative col-span-full row-span-3 grid grid-cols-subgrid grid-rows-subgrid -mb-8 bg-[#f5f8f9]! pt-0 pb-12"><div class="absolute right-0 -bottom-12 left-0 h-12 bg-background"></div><div class="stack-full-bleed"></div><div id="stack-main-column" class="relative grid max-w-full gap-24 sm:gap-40 stack-main"><div id="grid-24-container" class="@container/grid-cols-24 grid w-full grid-flow-dense grid-cols-24"><div id="stack-subgrid-item" class="@container isolate grid gap-2 col-span-full pb-0 pt-0"><p>To potentially enroll in one of the above Revolution Medicines clinical trials, Patients should discuss with their doctor whether they qualify for one of the above Revolution Medicines clinical trials.</p><p><span>These are select clinical trials only. To learn more about all our clinical trials, visit<!-- --> <a target="_blank" rel="noopener noreferrer" href="https://www.clinicaltrials.gov/search?spons=Revolution%20Medicines" class="underline">ClinicalTrials.gov</a></span><span>. </span>For questions on our clinical trials, please reach out to<!-- --> <a href="mailto:medinfo@revmed.com" class="leading-7 underline">medinfo@revmed.com</a> <!-- -->or<!-- --> <a class="text-nowrap" href="tel:18442738633">1-844-2-REVMED (1-844-273-8633).</a></p><p>The safety and efficacy of the agents and/or uses under investigation have not been established.</p></div></div></div></div></div> <div id="stack-root" class="stack-layout justify-center h-min max-h-min overflow-clip rounded-t-4xl rounded-b-none"><div class="relative col-span-full row-span-3 grid grid-cols-subgrid grid-rows-subgrid"><div class="stack-item-background -z-0 bg-cover bg-no-repeat!"><div style="background-image:url(/images/rnmostg4semj41kksvxm.webp);background-position:center" class="h-full"></div></div><div class="stack-full-bleed"></div><div id="stack-main-column" class="relative grid max-w-full gap-24 sm:gap-40 stack-main"><div id="grid-24-container" class="@container/grid-cols-24 grid w-full grid-flow-dense grid-cols-24"><div id="stack-subgrid-item" class="@container isolate grid gap-2 col-span-full @container/footer py-4"><div class="@tablet/footer:grid-cols-2 my-[5rem] grid w-full grid-cols-1 grid-rows-1 gap-y-8"><div class="@tablet/footer:items-start flex flex-col items-center justify-center gap-2"><img alt="Revolution Medicines Logo" loading="lazy" width="240" height="60" decoding="async" data-nimg="1" class="col-span-1 row-span-1 w-[12rem]" style="color:transparent" srcSet="/_next/image?url=%2Fimages%2Flogo-white.png&amp;w=256&amp;q=75 1x, /_next/image?url=%2Fimages%2Flogo-white.png&amp;w=640&amp;q=75 2x" src="/_next/image?url=%2Fimages%2Flogo-white.png&amp;w=640&amp;q=75"/><div class="@tablet/footer:text-left w-full text-center text-sm text-white">700 Saginaw Drive, Redwood City, CA 94063</div></div><div class="@tablet/footer:items-end flex flex-col items-center justify-center"><a href="https://www.revmed.com/ccpa-notice/"><button data-slot="button" class="cursor-pointer inline-flex items-center justify-center whitespace-nowrap font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-8 rounded-lg gap-1.5 px-3 has-[&gt;svg]:px-2.5 text-[1.15rem] font-[100]! text-white">CCPA Notice</button></a><a href="https://www.revmed.com/privacy-policy/"><button data-slot="button" class="cursor-pointer inline-flex items-center justify-center whitespace-nowrap font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-8 rounded-lg gap-1.5 px-3 has-[&gt;svg]:px-2.5 text-[1.15rem] font-[100]! text-white">Privacy Policy</button></a><a class="mb-4" href="https://www.revmed.com/contact-us/"><button data-slot="button" class="cursor-pointer inline-flex items-center justify-center whitespace-nowrap font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-8 rounded-lg gap-1.5 px-3 has-[&gt;svg]:px-2.5 text-[1.15rem] font-[100]! text-white">Contact Revolution Medicines</button></a><button data-slot="button" class="cursor-pointer inline-flex items-center justify-center whitespace-nowrap font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-8 rounded-lg gap-1.5 px-3 has-[&gt;svg]:px-2.5 cursor-default! text-[1.15rem] font-[100]! text-white no-underline!">© 2026 Revolution Medicines, Inc.</button><button data-slot="button" class="cursor-pointer inline-flex items-center justify-center whitespace-nowrap font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-8 rounded-lg gap-1.5 px-3 has-[&gt;svg]:px-2.5 cursor-default! text-[1.15rem] font-[100]! text-white no-underline!">RVMD-USA-00109 v2.0. Last Updated 02/26</button><div class="m-3"><a href="/patients"><button data-slot="button" class="cursor-pointer inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium transition-[color,box-shadow] disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg:not([class*=&#x27;size-&#x27;])]:size-4 shrink-0 [&amp;_svg]:shrink-0 outline-hidden focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive bg-primary text-primary-foreground shadow-xs hover:bg-primary/90 h-9 px-4 py-2 has-[&gt;svg]:px-3">Visit <!-- -->Patient<!-- --> Site</button></a></div></div></div></div></div></div></div></div></main></div><script src="/_next/static/chunks/webpack-aa9bcb5c9631707d.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0])</script><script>self.__next_f.push([1,"1:\"$Sreact.fragment\"\n2:I[94970,[],\"ClientSegmentRoot\"]\n3:I[55617,[\"37\",\"static/chunks/37-a26b13f87ab29070.js\",\"125\",\"static/chunks/125-7df5ca76a782050a.js\",\"701\",\"static/chunks/701-074e06a1b07af3d9.js\",\"420\",\"static/chunks/420-1993ecc7d3547568.js\",\"816\",\"static/chunks/816-8e3116e3fd24d1f0.js\",\"177\",\"static/chunks/app/layout-bab7f84191e188c2.js\"],\"default\"]\n4:I[87555,[],\"\"]\n5:I[31295,[],\"\"]\n7:I[83741,[\"37\",\"static/chunks/37-a26b13f87ab29070.js\",\"278\",\"static/chunks/278-a20f3f37cd2168a3.js\",\"125\",\"static/chunks/125-7df5ca76a782050a.js\",\"910\",\"static/chunks/910-d8833b5eb1740328.js\",\"722\",\"static/chunks/722-65461a18c3229669.js\",\"945\",\"static/chunks/945-635cfbeb3bb5f567.js\",\"458\",\"static/chunks/458-baba401b42b3259e.js\",\"220\",\"static/chunks/220-f3cafd169a707a9a.js\",\"133\",\"static/chunks/app/(pages)/layout-66e0a35eb32f6f03.js\"],\"default\"]\n9:I[90894,[],\"ClientPageRoot\"]\na:I[51944,[\"37\",\"static/chunks/37-a26b13f87ab29070.js\",\"278\",\"static/chunks/278-a20f3f37cd2168a3.js\",\"473\",\"static/chunks/473-dd0af661bef7f314.js\",\"125\",\"static/chunks/125-7df5ca76a782050a.js\",\"722\",\"static/chunks/722-65461a18c3229669.js\",\"945\",\"static/chunks/945-635cfbeb3bb5f567.js\",\"582\",\"static/chunks/582-7d7f0c699365d581.js\",\"977\",\"static/chunks/977-6a880f93ab31fcff.js\",\"816\",\"static/chunks/816-8e3116e3fd24d1f0.js\",\"404\",\"static/chunks/app/(pages)/clinical-trials/page-80c37838abeaa982.js\"],\"default\"]\nd:I[59665,[],\"OutletBoundary\"]\n10:I[59665,[],\"ViewportBoundary\"]\n12:I[59665,[],\"MetadataBoundary\"]\n14:I[26614,[],\"\"]\n:HL[\"/_next/static/media/2e6751bfd7d36be9-s.p.otf\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/otf\"}]\n:HL[\"/_next/static/media/90b139f15f0b76e6-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d567f6e95faecdec-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/ec2da9187a4470db.css\",\"style\"]\n:HL[\"/_next/static/css/fd5e99a03139be66.css\",\"style\"]\n:HL[\"/_next/static/css/cc7f9291227535e2.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"0:{\"P\":null,\"b\":\"d9ynGyxBkemmWIXtGajw7\",\"p\":\"\",\"c\":[\"\",\"clinical-trials\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"(pages)\",{\"children\":[\"clinical-trials\",{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/ec2da9187a4470db.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/fd5e99a03139be66.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}]],[\"$\",\"$L2\",null,{\"Component\":\"$3\",\"slots\":{\"children\":[\"$\",\"$L4\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L5\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":404}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]},\"params\":{},\"promise\":\"$@6\"}]]}],{\"children\":[\"(pages)\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L2\",null,{\"Component\":\"$7\",\"slots\":{\"children\":[\"$\",\"$L4\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L5\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":\"$0:f:0:1:1:props:children:1:props:slots:children:props:notFound:0:1:props:style\",\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":\"$0:f:0:1:1:props:children:1:props:slots:children:props:notFound:0:1:props:children:props:children:1:props:style\",\"children\":404}],[\"$\",\"div\",null,{\"style\":\"$0:f:0:1:1:props:children:1:props:slots:children:props:notFound:0:1:props:children:props:children:2:props:style\",\"children\":[\"$\",\"h2\",null,{\"style\":\"$0:f:0:1:1:props:children:1:props:slots:children:props:notFound:0:1:props:children:props:children:2:props:children:props:style\",\"children\":\"This page could not be found.\"}]}]]}]}]],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]},\"params\":\"$0:f:0:1:1:props:children:1:props:params\",\"promise\":\"$@8\"}]]}],{\"children\":[\"clinical-trials\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L4\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L5\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[[\"$\",\"$L9\",null,{\"Component\":\"$a\",\"searchParams\":{},\"params\":\"$0:f:0:1:1:props:children:1:props:params\",\"promises\":[\"$@b\",\"$@c\"]}],\"$undefined\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/cc7f9291227535e2.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}]],[\"$\",\"$Ld\",null,{\"children\":[\"$Le\",\"$Lf\",null]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[\"$\",\"$1\",\"d1ZtqkElTDxtjItOkeNNJ\",{\"children\":[[\"$\",\"$L10\",null,{\"children\":\"$L11\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]]}],[\"$\",\"$L12\",null,{\"children\":\"$L13\"}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$14\",\"$undefined\"],\"s\":false,\"S\":true}\n"])</script><script>self.__next_f.push([1,"6:{}\n8:{}\nb:{}\nc:{}\n"])</script><script>self.__next_f.push([1,"11:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}]]\ne:null\n"])</script><script>self.__next_f.push([1,"f:null\n13:[[\"$\",\"link\",\"0\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"150x176\"}]]\n"])</script></body></html>
